Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 12-Month Low - Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $5.19 and last traded at $5.34, with a volume of 4151746 shares changing hands. The stock had previously closed at $5.81.

Analyst Ratings Changes

Several research analysts recently issued reports on RXRX shares. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $8.25.

Recursion Pharmaceuticals Stock Down 11.9 %

The firm's 50 day moving average is $7.28 and its 200-day moving average is $6.96. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.70 billion, a PE ratio of -2.77 and a beta of 0.85.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million for the quarter, compared to analysts' expectations of $19.04 million. During the same quarter in the previous year, the company earned ($0.42) earnings per share. The company's revenue was down 57.8% on a year-over-year basis. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals during the 4th quarter worth $26,000. Private Trust Co. NA purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $27,000. GAMMA Investing LLC boosted its position in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after buying an additional 4,948 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.